# Master Feature Roadmap: P-adic VAE Bioinformatics Platform

**Version:** 1.0.0
**Created:** December 29, 2025
**Status:** Planning Phase
**Total Features:** 100

---

## Executive Summary

This roadmap defines 100 synergistic features to extend the P-adic VAE Bioinformatics Platform from its current state (11 disease analyzers, dual VAE architecture, hyperbolic geometry) into a comprehensive clinical and research platform.

### Current State (v5.11)
- 11 disease analyzers (HIV, TB, SARS-CoV-2, Influenza, HCV, HBV, RSV, MRSA, Malaria, Candida, Cancer)
- Dual VAE architecture with hyperbolic latent space
- 3-adic codon encoding
- Uncertainty quantification (MC Dropout, Evidential, Ensemble)
- Transfer learning pipeline (5 strategies)
- AlphaFold2 structure integration
- 2965 passing tests

### Target State (v7.0)
- 26+ disease analyzers
- Multi-prime hierarchical encoding (2-adic, 3-adic, 5-adic, 7-adic)
- Advanced hyperbolic geometry (multi-sheet, flows, adaptive curvature)
- Clinical integration (FHIR, REST API, reports)
- Federated learning for privacy-preserving training
- Real-time surveillance dashboard

---

## Document Index

| Document | Purpose |
|----------|---------|
| [01_FEATURE_CATALOG.md](./01_FEATURE_CATALOG.md) | Complete 100-feature descriptions |
| [02_IMPLEMENTATION_PHASES.md](./02_IMPLEMENTATION_PHASES.md) | Phased rollout plan |
| [03_DEFINITIONS_OF_DONE.md](./03_DEFINITIONS_OF_DONE.md) | Completion criteria per feature |
| [04_SYNERGY_MAP.md](./04_SYNERGY_MAP.md) | Feature interdependencies |
| [05_PRIORITY_MATRIX.md](./05_PRIORITY_MATRIX.md) | Impact vs effort analysis |

---

## Feature Categories Overview

| Category | Features | Description |
|----------|----------|-------------|
| **Disease Analyzers** | 1-15 | New pathogen support |
| **Encoding Methods** | 16-25 | P-adic extensions |
| **Hyperbolic Geometry** | 26-35 | Manifold innovations |
| **Uncertainty & Calibration** | 36-45 | Clinical-grade confidence |
| **Transfer Learning** | 46-55 | Cross-disease knowledge |
| **Architecture** | 56-70 | Model innovations |
| **Epistasis** | 71-80 | Mutation interactions |
| **Clinical Integration** | 81-90 | Healthcare deployment |
| **Training & Optimization** | 91-100 | Performance improvements |

---

## Implementation Timeline

```
2025 Q1 ─────────────────────────────────────────────────────────
         │ Phase 1: Foundation
         │ - Self-supervised pre-training (#51)
         │ - Conformal prediction (#36)
         │ - Clinical Decision API (#82)
         │ - 5-adic amino acid encoder (#16)
         │
2025 Q2 ─────────────────────────────────────────────────────────
         │ Phase 2: Disease Expansion
         │ - Dengue, Zika, Norovirus (#1-3)
         │ - Hierarchical VAE (#56)
         │ - VQ-VAE for codons (#57)
         │
2025 Q3 ─────────────────────────────────────────────────────────
         │ Phase 3: Advanced Features
         │ - Tensor epistasis (#71)
         │ - Domain adversarial transfer (#46)
         │ - Multi-sheet hyperbolic (#26)
         │
2025 Q4 ─────────────────────────────────────────────────────────
         │ Phase 4: Clinical Deployment
         │ - FHIR integration (#81)
         │ - Surveillance dashboard (#88)
         │ - Federated learning (#100)
         │
2026 Q1 ─────────────────────────────────────────────────────────
         │ Phase 5: Scale & Optimize
         │ - Remaining disease analyzers (#4-15)
         │ - Neural architecture search (#99)
         │ - Knowledge distillation (#98)
         │
2026 Q2 ─────────────────────────────────────────────────────────
         │ Phase 6: Research Frontier
         │ - Remaining encoding methods (#17-25)
         │ - Advanced hyperbolic (#27-35)
         │ - Full epistasis suite (#72-80)
```

---

## Success Metrics

### Technical Metrics
| Metric | Current | Target |
|--------|---------|--------|
| Disease analyzers | 11 | 26+ |
| Mean Spearman correlation | 0.89 | 0.92 |
| Uncertainty calibration error | TBD | <0.03 |
| Test coverage | 86% | 90% |
| Inference speed | 6M/sec | 10M/sec |

### Clinical Metrics
| Metric | Current | Target |
|--------|---------|--------|
| FHIR compliance | None | Full |
| Clinical API endpoints | 0 | 50+ |
| Hospital integrations | 0 | 5+ |
| Regulatory submissions | 0 | FDA 510(k) |

### Research Metrics
| Metric | Current | Target |
|--------|---------|--------|
| Publications | 0 | 3+ |
| Novel p-adic encodings | 1 (3-adic) | 4+ |
| Hyperbolic innovations | 1 | 5+ |
| Open datasets | 0 | 3+ |

---

## Risk Assessment

### High Risk
- **Regulatory approval delays** - Mitigation: Early FDA pre-submission
- **Clinical validation gaps** - Mitigation: Hospital partnerships
- **Federated learning complexity** - Mitigation: Phased rollout

### Medium Risk
- **Transfer learning negative transfer** - Mitigation: Domain adversarial training
- **Hyperbolic numerical instability** - Mitigation: Lorentz model fallback
- **Epistasis computational cost** - Mitigation: Sparse tensor factorization

### Low Risk
- **New disease analyzer failures** - Mitigation: Extensive test suites
- **Encoding method performance** - Mitigation: Ablation studies
- **API breaking changes** - Mitigation: Versioned endpoints

---

## Stakeholders

| Role | Responsibility |
|------|----------------|
| **Research Lead** | Feature prioritization, technical direction |
| **Clinical Lead** | Hospital partnerships, regulatory strategy |
| **Engineering Lead** | Implementation, testing, deployment |
| **Data Science Lead** | Model evaluation, benchmarking |
| **Product Owner** | Roadmap alignment, stakeholder communication |

---

## Change Log

| Date | Version | Changes |
|------|---------|---------|
| 2025-12-29 | 1.0.0 | Initial roadmap creation |

---

## Next Steps

1. Review and approve feature prioritization
2. Assign feature owners
3. Create detailed sprint plans for Phase 1
4. Establish baseline metrics
5. Begin Phase 1 implementation
